Imigran Sprint

Sumatriptan, the active ingredient in Imigran Sprint, is a Triptan presented as a 100 mg orally disintegrating tablet for oral use. It is indicated for the acute treatment of migraine attacks, with or without aura, in adult patients.

GNH USA supplies Imigran Sprint as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets. The product is manufactured to European Union standards and distributed under strict quality controls. It meets all applicable pharmacopoeial specifications for safety and efficacy.

Sumatriptan is a selective serotonin 5‑HT1 receptor agonist used in the acute management of migraine.

Migraine with aura: rapid relief of headache and associated neurological symptoms. Migraine without aura: reduction of headache intensity and duration. Acute migraine attacks (any type): abortive treatment to alleviate pain and associated nausea.

Common Side Effects: - Tingling or numbness in the face, fingers, or toes. - Chest discomfort or tightness. - Dizziness or light‑headedness. - Nausea or abdominal pain. - Dry mouth. - Fatigue.

Serious or Rare Side Effects: - Coronary vasospasm leading to chest pain or myocardial ischemia. - Severe hypertension or hypertensive crisis. - Serotonin syndrome, especially with serotonergic agents. - Allergic reactions such as rash, angioedema, or anaphylaxis. - Cardiac arrhythmias. - Stroke or transient ischemic attack.

Before prescribing, evaluate cardiovascular risk and contraindications.

Assess cardiovascular history: avoid use in patients with ischemic heart disease or uncontrolled hypertension. Avoid concomitant ergotamine: increased risk of vasospasm. Use caution in patients with severe hepatic impairment. Do not exceed the recommended dose frequency as directed by the prescriber. Avoid in patients with known hypersensitivity to sumatriptan or any tablet excipients. Store at ambient temperature: keep in the original pack, protect from moisture.

Sumatriptan may interact with several drug classes; monitoring is essential.

Major Interactions (Avoid): - MAO inhibitors: risk of serotonin syndrome. - Ergot derivatives: additive vasoconstrictive effects. - Other triptans: cumulative serotonergic activity.

Moderate Interactions (Monitor Closely): - SSRIs or SNRIs: potential for serotonin syndrome. - Beta‑blockers: may increase plasma concentrations of sumatriptan. - Strong CYP3A4 inhibitors (e.g., ketoconazole): elevate exposure and side‑effect risk.